References

1. Pui, C.-H.; Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Eng. J. Med. 2006, 354, 166–178.
2. Frishman-Levy, L.; Izraeli, S. Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. Br. J. Haematol. 2017, 176, 157–167.
3. Conter, V.; Arico, M.; Valsecchi, M.G.; Basso, G.; Biondi, E.; Madon, F.; Mandelli, F.; Paolucci, G.; Pession, C.; Rizzari, C.; et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982–1995. Leukemia 2000, 14, 2196–2204.
4. Gaynon, P.S.; Trigg, M.E.; Heerema, N.A.; Sensel, M.G.; Sather, H.N.; Hammond, G.D.; Bleyer, W.A. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995. Leukemia 2000, 14, 2223–2233.
5. Kamps, W.A.; Bokkerink, J.P.; Hakvoort-Cammel, F.G.; Veerman, A.J.P.; Weening, R.S.; van Wering, E.R.; van Weerden, J.F.; Hermans, J.; Slater, R.; van den Berg, E.; et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991–1996). Leukemia 2002, 16, 1099–1111.
6. Pui, C.H.; Howard, S.C. Current management and challenges of malignant disease in the CNS in pediatric leukemia. Lancet Oncol. 2008, 9, 257–268.
7. Lenk, L.; Alsadeq, A.l.; Schwebe, D.M. Involvement of the central nervous system in acute lymphoblastic leukemia: Opinions on molecular mechanisms and clinical imlications based on recent data. Cancer Met. Rev. 2020, 39, 173–187.
8. Aspelund, A.; Antila, S.; Proulx, S.T.; Karlsen, T.V.; Karaman, S.; Detmar, M.; Wiig, H.; Alitalo, K. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 2015, 212, 991–999.
9. Louveau, A.; Smirnov, I.; Keyes, T.J.; Eccles, J.D.; Rouhani, S.J.; Peske, J.D.; Derecki, N.C.; Castle, D.; Mandell, J.W.; Lee, K.S.; et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523, 337–341.
10. Louveau, A.; Herz, J.; Alme, M.N.; Salvador, A.F.; Dong, M.Q.; Viar, K.E.; Herod, S.G.; Knopp, J.; Setliff, J.C.; Lupi, A.L.; et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 2018, 21, 1380–1391.
11. Yao, H.; Price, T.T.; Cantelli, G.; Ngo, B.; Warner, M.J.; Olivere, L.; Ridge, S.M.; Jablonski, E.M.; Therrien, J.; Tannheimer, S.; et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 2018, 560, 55–60.
12. Silverman, L.B.; Declerck, L.; Gelber, R.D.; Dalton, V.K.; Asselin, B.L.; Barr, R.D.; Clavell, L.A.; Hurwitz, C.A.; Moghrabi, A.; Samson, Y.; et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995). Leukemia 2000, 14, 2247–2256.
13. Alsadeq, A.; Schewe, D.M. Acute lymphoblastic leukemia of the central nervous system: On the role of PBX1. Haematologica 2017, 102, 611–613.
14. Jeha, S.; Pei, D.; Raimondi, S.C.; Onciu, M.; Campana, D.; Cheng, C.; Sandlund, J.T.; Ribeiro, R.C.; Rubnitz, J.E.; Howard, S.C.; et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009, 23, 1406–1409.
15. Van der Velden, V.H.; de Launaij, D.; de Vries, J.F.; de Haas, V.; Sonneveld, E.; Voerman, J.S.; de Bie, M.; Revesz, T.; Avigad, S.; Yeoh, A.E.; et al. New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia. Br. J. Haematol. 2016, 172, 769–781.
16. Jin, M.-W.; Xu, S.-M.; An, Q. Central nervous disease in pediatric patients during acute lymphoblastic leukemia (ALL): A review. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 6015–6019.
17. Bürger, B.; Zimmermann, M.; Mann, G.; Kühl, J.; Löning, L.; Riehm, H.; Reiter, A.; Schrappe, M. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J. Clin. Oncol. 2003, 21, 184–188.
18. Del Principe, M.I.; Maurillo, L.; Buccisano, F.; Sconocchia, G.; Cefalo, M.; de Santis, G.; Veroli, A.D.; Ditto, C.; Nasso, D.; Postorino, M.; et al. Central nervous system involvement in adult acute lymphoblastic leukemia: Diagnostic tools, prophylaxis, and therapy. Med. J. Hem. Inf. Dis. 2014, 6, e2014075.
19. Yousafzai, Y.M.; Smith, L.; Smith, A.; Bhatti, S.; Gardiner, M.; Cousins, A.; Fee, F.; Chudleigh, S.; Spence, A.; Taylor, W.; et al. Use of quantitative polymerase chain reaction (qPCR) for the diagnosis and monitoring of CNS leukaemia. Leuk. Res. 2019, 87, 106232.
20. Thastrup, M.; Marquart, H.V.; Levinsen, M.; Grell, K.; Abrahamsson, J.; Albertsen, B.K.; Frandsen, T.L.; Harila-Saari, A.; Lähteenmäki, P.M.; Niinimäki, R.; et al. on behalf of the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: A Nordic Society of Pediatric Hematology and Oncology study. Leukemia 2020, 34, 336–346.
21. Omans, A.C.; Barker, B.E.; Forman, E.N.; Cornell, C.J.; Dickerman, J.D.; Truman, J.T. Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis. Blood 1990, 76, 1807–1811.
22. Cancela, C.S.P.; Murao, M.; Barcelos, J.M.; Furtado, V.M.; Oliveira, B.M.D. Central nervous system involvement in acute lymphoblastic leukemia: Diagnosis by immunophenotyping. J. Bras. Patol. Med. Lab. 2013, 49, 260–263.
23. Martinez-Laperche, C.; Gomez-Garcia, A.M.; Lassaletta, A.; Moscardo, C.; Vivanco, J.L.; Ramirez, M. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. Am. J. Hematol. 2013, 88, 359–364.
24. Liang, Y.; Ca, Q.; Zhai, Z.M.; Wang, N.L. A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia: A single Chinese center’s experience. J. Pediatr. Hematol. Oncol. 2013, 35, 388–393.
25. Ranta, S.; Nilsson, F.; Harila-Saari, A.; Saft, L.; Tani, E.; Söderhäll, S.; Porwit, A.; Hultdin, M.; Noren-Nyström, U.; Heyman, M. Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid. Pediatr. Blood Cancer 2015, 62, 951–956.
26. Biojone, E.; Queiróz Rde, P.; Valera, E.T.; Odashima, N.S.; Takayanagui, O.M.; Viana, M.B.; Tone, L.G.; Scrideli, C.A. Minimal residual disease in cerebrospinal fluid at diagnosis: A more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia. Leuk. Lymphoma 2012, 53, 89–95.
27. Egyed, B.; Kutszegi, N.; Sági, J.C.; Gézsi, A.; Rzepiel, A.; Visnovitz, T.; Lőrincz, P.; Müller, J.; Zombori, M.; Szalai, C.; et al. MicroRNA-181a as novel liquid biopsy marker of central nervous system involvement in pediatric acute lymphoblastic leukemia. J. Transl. Med. 2020, 18, 250.
28. Stucki, A.; Cordey, A.S.; Monai, N.; Deflaugergues, J.C.; Schapira, H.; Spertini, O. Cleaved L-selectin concentrations in meningeal leukemia. Lancet 1995, 345, 286–289.
29. Lee, W.; Kim, S.J.; Lee, S.; Kim, J.; Kim, M.; Lim, J.; Kim, Y.; Cho, B.; Lee, E.J.; Han, K. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia. Ann. Clin. Lab. Sci. 2005, 35, 407–412.
30. Alsadeq, A.; Lenk, L.; Vadakumchery, A.; Cousins, A.; Vokuhl, C.; Khadour, A.; Vogiatzu, F.; Seyfried, F.; Meyer, L.-H.; Cario, G.; et al. IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 2018, 132, 1614–1617.
31. Tang, Y.T.; Jiang, F.; Guo, L.; Si, M.Y.; Jiao, X.Y. The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. J. Neurooncol. 2013, 112, 329–338.
32. Ncesoy-Özdemir, S.; ŞAhin, G.; Bozkurt, C.; Ören, A.C.; Balkaya, E.; Ertem, U. The relationship between cerebrospinal fluid osteopontin level and central nervous system involvement in childhood acute leukemia. Turk. J. Pediatr. 2013, 55, 42–49.
33. Mikhael, N.L.; Gendi, M.; Hassab, H.; Megahed, E.A. Evaluation of multiplexed biomarkers in assessment of CSF infiltration in pediatric acute lymphoblastic leukemia. Int. J. Hematol. Oncol. 2019, 8, IJH22.
34. Guo, L.; Ren, H.; Zeng, H.; Gong, Y.; Ma, X. Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: A pilot study. OncoTargets Ther. 2019, 12, 3859–3868.
35. Scrideli, C.A.; Queiroz, R.P.; Takayanagui, O.M.; Bernardes, J.E.; Melo, E.V.; Tone, L.G. Molecular diagnosis of leukemic cerebrospinal fluid cells in children with newly diagnosed acute lymphoblastic leukemia. Haematologica 2004, 89, 1013–1015.
36. Choi, J.K.; Jeha, S.; Zheng, J.; Carlton, V.; Faham, M.; Pui, C.-H. Assessment of central nervous system involvement in pediatric acute lymphoblastic leukemia patients using next-generation sequencing method. Blood 2015, 126, 4981.
37. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–221.
38. Lim, E.L.; Trinh, D.L.; Ries, R.E.; Wang, J.; Gerbing, R.B.; Ma, Y.; Topham, J.; Hughes, M.; Pleasance, E.; Mungall, A.J.; et al. MicroRNA expression-based model indicates event-free survival in pediatric acute myeloid leukemia. J. Clin. Oncol. 2017, 35, 3964–3977.
39. Szcepanke, J. Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review. World J. Clin. Oncol. 2020, 11, 348–369.
40. Rubenstein, J.L.; Wong, V.S.; Kadoch, C.; Gao, H.X.; Barajas, R.; Chen, L.; Josephson, S.A.; Lowell, C. Cxcl13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 2013, 12, 4740–4748.
41. Buonamici, S.; Trimarchi, T.; Ruocco, M.G.; Reavie, L.; Cathelin, S.; Mar, B.G.; Klinakis, A.; Luyanov, Y.; Tseng, Y.; Tseng, J.-C.; et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009, 459, 1000–1004.
42. Bastos, A.C.S.F.; Blunck, C.B.; Emerenciano, M.; Gimba, E.R.P. Osteopontin and their roles in hematological malignancies: Splice variants on the new avenues. Cancer Lett. 2017, 408, 138–143.
43. Boyerinas, B.; Zafrir, M.; Yesilkanal, A.E.; Price, T.T.; Hyjek, E.M.; Sipkins, D.A. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013, 121, 4821–4831.
44. Marroquin, C.E.; Downey, L.; Guo, H.; Kuo, P.C. Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunol. Lett. 2004, 95, 109–112.
45. Chiang, P.K.; Lam, M.A.; Luo, Y. The many faces of amyloid beta in Alzheimer’s disease. Curr. Mol. Med. 2008, 8, 580–584.
46. Gilchrist, A.; Au, C.E.; Hiding, J.; Bell, A.W.; Fernandez-Rodriguez, J.; Lesimple, S.; Nagaya, H.; Roy, L.; Gosline, S.J.; Hallett, M. Quantitative proteomics analysis of the secretory pathway. Cell 2006, 127, 1265–1281.
47. Cilento, E.M.; Jin, L.; Stewart, T.; Shi, M.; Sheng, L.; Zhang, J.J. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer’s and Parkinson’s diseases. J. Neurochem. 2019, 151, 397–416.
48. Henderson, T.O.; Friedman, D.L.; Meadows, A.T. Childhood cancer survivors: Transition to adult-focused risk-based care. Pediatrics 2010, 126, 129–136.
49. Kadan-Lottick, N.S.; Zeltzer, L.K.; Liu, Q.; Yasui, Y.; Ellenberg, L.; Gioia, G.; Robison, L.L.; Krull, K.R. Neurocognitive functioning in adult survivors of childhood noncentral nervous system cancers. J. Natl. Cancer Inst. 2010, 102, 881–893.
50. Oeffinger, K.C.; Nathan, P.C.; Kremer, L.C. Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Hematol. Oncol. Clin. N. Am. 2010, 24, 129–149.
51. Zeltzer, L.K.; Recklitis, C.; Buchbinder, D.; Zebrack, B.; Casillas, J.; Tsao, J.C.; Lu, Q.; Krull, K. Psychological status in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 2009, 27, 2396–2404.
52. Hearps, S.; Seal, M.; Andersn, V.; McCarthy, M.; Connellan, M.; Downie, P.; De Luca, C. The relationship between cognitive and neuroimaging outcomes in children treated for acute lymphoblastic leukemia with chemotherapy only: A systematic review. Ped. Blood Cancer 2017, 64, 225–233.
53. Krull, K.R.; Hardy, K.K.; Kahalley, L.; Schuitema, I.; Kesler, S.R. Neurocognitive outcomes and interventons in long-term survivors of childhood cancer. J. Clin. Oncol. 2018, 36, 2181–2190.
54. Hardy, K.K.; Embry, L.; Kairalla, J.A.; Helian, S.; Devidas, M.; Armstrong, D.; Hunger, S.; Carroll, W.L.; Larsen, E.; Raetz, E.A.; et al. Neurocognitive functioning of children treated for high risk B-acute lymphoblastic leukemia randomly assigned to different methotrexate and corticosteroid treatment strategies: A report from the Children’s Oncology Group. J. Clin. Oncol. 2017, 35, 2700–2707.
55. Liu, W.; Cheung, Y.T.; Conklin, H.M.; Jacola, L.M.; Srivastava, D.; Nolan, V.G.; Zhang, H.; Gurney, J.G.; Huang, I.-C.; Robinson, L.L.; et al. Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. J. Cancer Surv. 2018, 12, 398–406.
56. Sleurs, C.; Lemiere, J.; Vercruysse, T.; Nolf, N.; van Calster, B.; Deprez, S.; Renard, M.; Vandecruys, E.; Benoit, Y.; Uyttebroeck, A. Intellectual development of childhood ALL patients: A multicenter longitudinal study. Psychooncology 2017, 26, 508–514.
57. Duffner, P.K.; Armstrong, F.D.; Chen, L.; Helton, K.J.; Brecher, M.L.; Bell, B.; Chauvenet, A.R. Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): A methotrexate consequence? A report from the Children’s Oncology Group. J. Pediatr. Hematol. Oncol. 2014, 36, 8–15.
58. Anderson, F.S.; Kunin-Batson, A.S. Neurocognitive late effects of chemotherapy in children: The past 10 years of research on brain structure and function. Pediatr. Blood Cancer 2009, 52, 159–164.
59. Ashford, J.; Schoffstall, C.; Reddick, W.E.; Leone, C.; Laningham, F.H.; Glass, J.O.; Pei, D.; Cheng, C.; Pui, C.H.; Conklin, H.M. Attention and working memory abilities in children treated for acute lymphoblastic leukemia. Cancer 2010, 116, 1173–1186.
60. Buizer, A.I.; de Sonneville, L.M.; Veerman, A.J. Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: A critical review of the literature. Pediatr. Blood Cancer 2009, 52, 447–454.
61. Lofstad, G.E.; Reinfjell, T.; Hestad, K.; Diseth, T.H. Cognitive outcome in children and adolescents treated for acute lymphoblastic leukaemia with chemotherapy only. Acta Paediatr. 2009, 98, 180–186.
62. Moleski, M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch. Clin. Neuropsychol. 2000, 15, 603–630.
63. Von der Weid, N.; Mosimann, I.; Hirt, A.; Wacker, P.; Nenadov Beck, M.; Imbach, P.; Caflisch, U.; Niggli, F.; Feldges, A.; Wagner, H.P. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: Age- and sex-related differences. Eur. J. Cancer 2003, 39, 359–365.
64. Jansen, N.C.; Kingma, A.; Schuitema, A.; Bouma, A.; Veerman, A.J.; Kamps, W.A. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. J. Clin. Oncol. 2008, 26, 3025–3030.
65. Bhojwani, D.; Sabin, N.D.; Pei, D.; Khan, R.B.; Panetta, J.C.; Krull, K.R.; Inaba, H.; Rubnitz, J.E.; Metzger, M.L.; Howard, S.C.; et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2014, 32, 949–959.
66. Carey, M.E.; Haut, M.W.; Reminger, S.L.; Hutter, J.J.; Theilmann, R.; Kaemingk, K.L. Reduced frontal white matter volume in long-term childhood leukemia survivors: A voxel-based morphometry study. Am. J. Neuroradiol. 2008, 29, 792–797.
67. Genschaft, M.; Huebner, T.; Plessow, F.; Ikonomidou, V.N.; Abolmaali, N.; Krone, F.; Hoffmann, A.; Holfeld, E.; Vorwerk, P.; Kramm, C.; et al. Impact of chemotherapy for childhood leukemia on brain morphology and function. PLoS ONE 2014, 8, e78599.
68. Asato, R.; Akiyama, Y.; Ito, M.; Kubota, M.; Okumura, R.; Miki, Y.; Konishi, J.; Mikawa, H. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 1992, 70, 1997–2004.
69. Dellani, P.R.; Eder, S.; Gawehn, J.; Fellgiebel, A.; Müller, M.J.; Schmidberger, H.; Stoeter, P.; Gutjahr, P. Late structural alterations of cerebral white matter in long-term survivors of childhood leukemia. J. Magn. Reson. Imaging 2008, 27, 1250–1255.
70. Van der Plas, E.; Schachar, R.J.; Hitzler, L.; Crosbie, J.; Guger, S.L.; Spiegler, B.J.; Ito, S.; Nieman, B.J. Brain structure, working memory and response inhibition in childhood leukemia. Brain Behav. 2016, 29, e00621.
71. Reddick, W.E.; Glass, J.O.; Johnson, D.P.; Laningham, F.H.; Pui, C.-H. Voxel-based analysis of T2 hyperintensities in white matter during treatment of childhood leukemia. Am. J. Neuroradiol. 2009, 30, 1947–1954.
72. Deprez, S.; Amant, F.; Smeets, A.; Peeters, R.; Leemans, A.; Van Hecke, W.; Verhoeven, J.S.; Christiaens, M.R.; Vandenberghe, J.; Vandenbulcke, M.; et al. Longitudinal assessment of chemotherapy-induced changes in cerebral white matter and its correlation with impaired cognitive functioning. J. Clin. Oncol. 2012, 30, 274–281.
73. Khong, P.-L.; Leung, L.H.T.; Fung, A.S.M.; Fong, D.Y.T.; Qiu, D.; Kwong, D.L.W.; Ooi, G.-C.; McAlonan, G.; Cao, G.; Chan, G.C.F. White matter anisotropy in post-treatment childhood cancer survivors: Preliminary evidence of association with neurocognitive function. J. Clin. Oncol. 2006, 24, 884–890.
74. Edelmann, M.N.; Krull, K.R.; Liu, W.; Glass, J.O.; Ji, Q.; Ogg, R.J.; Sabin, N.D.; Srivastava, D.K.; Robison, L.L.; Hudson, M.M.; et al. Diffusion tenson imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia. Brain 2014, 137, 2973–2983.
75. ElAlfy, M.; Ragab, I.; Azab, I.; Amin, S.; Abdel-Maguid, M. Neurocognitive outcome and white matter anisotropy in childhood acute lymphoblastic leukemia survivors treated with different protocols. Pediatr. Hematol. Oncol. 2014, 31, 194–204.
76. Kesler, S.R.; Gugel, M.; Huston-Warren, E.; Watson, C. Atypical structural connectome organization and cognitive impairment in young survivors of acute lymphoblastic leukemia. Brain Connect. 2016, 6, 273–282.
77. Sleurs, C.; Lemiere, J.; Christiaens, D.; Billiet, T.; Peeters, R.; Sunaert, S.; Uyttebroeck, A.; Deprez, S. Advanced MR diffusion imaging and chemotherapy-related changes in cerebral white matter microstructure of survivors of childhood bone and soft tissue sarcoma. Hum. Brain Mapp. 2018, 39, 3375–3387.
78. Tamnes, C.T.; Zeller, B.; Amlien, I.K.; Kanellopoulos, A.; Andersson, S.; Due- Tønnessen, P.; Ruud, E.; Walhovd, K.B.; Fjell, A.M. Cortical surface area and thickness in adult survivors of pediatric acute lymphoblastic leukemia. Pediatr. Blood Cancer 2015, 62, 1027–1034.
79. Krull, K.R.; Cheung, Y.T.; Liu, W.; Fellah, S.; Reddick, W.E.; Brinkman, T.M.; Kimberg, C.; Ogg, R.; Srivastava, D.; Pui, C.H.; et al. Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2016, 34, 2644–2653.
80. Cheung, Y.T.; Krull, K.R. Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. Neurosci. Biobehav. Rev. 2015, 53, 108–120.
81. Oesterlundh, G.; Kjellmer, I.; Lannering, B.; Rosengren, L.; Nilsson, U.A.; Márky, I. Neurochemical markers of brain damage in cerebrospinal fluid during induction treatment of acute lymphoblastic leukemia in children. Pediatr. Blood Cancer 2008, 50, 793–798.
82. Cheung, Y.T.; Khan, R.B.; Liu, W.; Brinkman, T.M.; Edelmann, M.N.; Reddick, W.E.; Pei, D.; Panoskaltsis-Mortari, A.; Srivastava, D.; Cheng, C.; et al. Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury with Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia. JAMA Oncol. 2018, 4, e180089.
83. Gust, J.; Finney, O.C.; Li, D.; Hicks, R.M.; Futrell, R.B.; Gamble, D.N.; Rawlings-Rhea, S.D.; Khalatbari, H.K.; Ishak, G.E.; Duncan, C.E.; et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann. Neurol. 2019, 86, 42–54.
84. Chiaretti, A.; Ruggiero, A.; Coccia, P.; Antonelli, A.; Pierri, F.; Barone, G.; Attina, G.; Iuvone, L.; Maurizi, P.; Riccardi, R. Expression of liquoral neuroprotection markers in children with acute lymphoblastic leukemia. Leuk. Res. 2011, 35, 1467–1471.
85. Viacha, V.; Eliopoulou, M.; Haidas, S.; Beratis, N.G. Correlation of cerebrospinal fluid betal-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate. Pediatr. Blood Cancer 2004, 42, 350–356.
86. Van Gool, S.W.; De Meyer, G.; van de Voorde, A.; Vanmechelen, E.; Vanderstichele, H. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 2003, 25, 471–480.
87. Krawczuk-Rybak, M.; Grabowska, A.; Protal, P.T.; Muszynska-Roslan, K.; Braszko, J. Intellectual functioning of childhood leukemia survivors—Relation to Tau protein—A marker of white matter injury. Adv. Med. Sci. 2012, 57, 266–272.
88. Caron, J.E.; Krull, K.R.; Hockenberry, M.; Jain, N.; Kaemingk, K.; Moore, I.M. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediatr. Blood Cancer 2009, 53, 551–556.
89. Cole, P.D.; Beckwith, K.A.; Vijayanathan, V.; Roychowdhury, S.; Smith, A.K.; Kamen, B.A. Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. Pediatr. Neurol. 2009, 40, 34–41.
90. Taylor, O.A.; Hockenberry, M.J.; McCarthy, K.; Gundy, P.; Montgomery, D.; Ross, A.; Scheurer, M.E.; Moore, I.M. Evaluation of Biomarkeres of Oxidative Stress and Apoptosis in Patients with Severe Methotrexate Neurotoxicity: A case Series. J. Pediatr. Oncol. Nurs. 2015, 32, 320–325.
91. Moore, I.M.K.; Koerner, K.M.; Gundy, P.M.; Montgomery, D.W.; Insel, K.C.; Harris, L.L.; Taylor, O.A.; Hockenberry, M.J. Changes in oxidant defense, apoptosis and cognitive abilities during treatment for childhood leukemia. Biol. Res. Nurs. 2018, 20, 393–402.
92. Yu, Q.; Zhong, X.; Chen, B.; Feng, Y.; Ma, M.; Diamond, C.A.; Voeller, J.S.; Kim, M.; DeSantes, K.B.; Capitini, C.M.; et al. Isobaric Labeling Strategy Utilizing 4-Plex N, N-Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute Lymphoblastic Leukemia. J. Proteome Res. 2020, 19, 2606–2616.
93. Brown, A.L.; Sok, P.; Taylor, O.; Woodhouse, J.P.; Bernhardt, M.B.; Raghubar, K.P.; Kahalley, L.S.; Lupo, P.J.; Hockenberry, M.J.; Scheuer, M.E. Cerebrospinal Fluid Metabolomic Profiles Associated with Fatigue During Treatment for Pediatric Acute Lymphoblastic Leukemia. J. Pain Symptom Manag. 2020.
94. Stenzel, S.L.; Krull, K.R.; Hockenberry, M.; Jain, N.; Kaemingk, K.; Miketova, P.; Moore, I.M. Oxidative stress and neurobehavioral problems in pediatric acute lymphoblastic leukemia patients undergoing chemotherapy. J. Pediatr. Hematol. Oncol. 2010, 32, 113–118.
95. Hockenberry, M.J.; Taylor, O.A.; Gundy, P.M.; Ross, A.K.; Pasvogel, A.; Montgomery, D.; Ribbeck, P.; McCarthy, K.; Moore, I. F2-Isoprostanes: A measure of oxidative stress in children receiving treatment for leukemia. Biol. Res. Nurs. 2014, 16, 303–309.
96. Hesse, C.; Rosengren, L.; Vanmechelen, E.; Vanderstichele, H.; Jensen, C.; Davidsson, P.; Blennow, K. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J. Alzheimer’s Dis. 2000, 2, 199–206.
97. Kay, A.; Petzold, A.; Kerr, M.; Keir, G.; Thompson, E.; Nicoll, J. Temporal alterations in cerebrospinal fluid amyloid β-protein and apolipoprotein E after subarachnoid hemorrhage. Stroke 2003, 34, e240–e243.
98. Polihronis, M.; Paizis, K.; Carter, G.; Sedal, L.; Murphy, B. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. J. Neurol. Sci. 1993, 115, 230–233.
99. Vranová, H.P.; Hényková, E.; Mareš, J.; Kaiserová, M.; Menšíková, K.; Vaštík, M.; Hluštík, P.; Zapletalová, J.; Strnad, M.; Stejskal, D.; et al. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J. Neurol. Sci. 2016, 361, 117–121.
100. Heywood, W.E.; Galimberti, D.; Bliss, E.; Sirka, E.; Paterson, R.W.; Magdalinou, N.K.; Carecchio, M.; Reid, E.; Heslegrave, A.; Fenoglio, C.; et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol. Neurodegener. 2015, 10, 64.
101. Rasmussen, K.K.; Falkesgaard, M.H.; Winther, M.; Roed, N.K.; Quistgaard, C.L.; Teisen, M.N.; Edslev, S.M.; Petersen, D.L.; Aljubouri, A.; Christensen, C.; et al. NCAM2 Fibronectin type-III domains form a rigid structure that binds and activates the Fibroblast Growth Factor Receptor. Sci. Rep. 2018, 8, 8957.
102. Sakurai, T. The role of NrCAM in neural development and disorders—Beyond a simple glue in the brain. Mol. Cell. Neurosci. 2012, 49, 351–363.
103. Poltorak, M.; Frye, M.A.; Wright, R.; Hemperly, J.J.; George, M.S.; Pazzaglia, P.J.; Jerrels, S.A.; Post, R.M.; Freed, W.J. Increased neural cell adhesion molecule in the CSF of patients with mood disorder. J. Neurochem. 1996, 66, 1532–1538.
104. Dennis, E.L.; Jahanshad, N.; Braskie, M.N.; Warstadt, N.M.; Hibar, D.P.; Kohannim, O.; Nir, T.M.; McMahon, K.L.; de Zubicaray, G.I.; Montgomery, G.W.; et al. Obesity gene NEGR1 associated with white matter integrity in healthy young adults. NeuroImage 2014, 102, 548–557.
105. Li, F.; Tian, X.; Zhou, Y.; Zhu, L.; Wang, B.; Ding, M.; Pang, H. Dysregulated expression of secretogranin III is involved in neurotoxin induced dopaminergic neuron apoptosis. J. Neurosci. Res. 2012, 90, 2237–2246.
106. Brudno, J.N.; Kochenderfer, J.N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 2018, 15, 31–46.
107. Annesley, C.E.; Summers, C.; Ceppi, F.; Gardner, R.A. The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia. Clin. Pharm. Ther. 2018, 103, 591–598.
108. Fesnak, A.D.; June, C.H.; Levine, B.L. Engineered T cells: The promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 2016, 16, 566–581.
109. Gust, J.; Taraseviciute, A.; Turtle, C.J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 2018, 32, 1091–1101.
110. Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 2019, 25, 625–638.
111. Taraseviciute, A.; Tkachev, V.; Ponce, R.; Turtle, C.J.; Snyder, J.M.; Liggitt, H.D.; Myerson, D.; Gonzalez-Cuyar, L.; Baldessari, A.; English, C.; et al. Chimeric antigen receptor T cell-mediated neurotoxicity in non-human primates. Cancer Discov. 2018, 8, 750–763.
112. Gust, J.; Hay, K.A.; Hanafi, L.A.; Li, D.; Myerson, D.; Gonzalez-Cuyar, L.F.; Yeung, C.; Liles, C.; Wurfel, M.; Lopez, J.A.; et al. Endothelial activation and bloodbrain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017, 7, 1404–1419.
113. Norelli, M.; Camisa, B.; Barbiera, G.; Falcone, L.; Purevdori, A.; Genua, M.; Sanvito, F.; Ponzoni, M.; Doglioni, C.; Cristofori, P.; et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 2018, 24, 739–748.